anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The human neck is a unique mechanical structure, highly flexible but fatigue prone. The rising prevalence of neck pain and chronic injuries has been attributed to increasing exposure to fatigue loading in activities such as prolonged sedentary work and overuse of electronic devices. However, a causal relationship between fatigue and musculoskeletal mechanical changes remains elusive. This work aimed to establish this relationship through a unique experiment design, inspired by a cantilever beam mechanical model of the neck, and an orchestrated deployment of advanced motion-force measurement technologies including dynamic stereo-radiographic imaging. As a group of 24 subjects performed sustained-till-exhaustion neck exertions in varied positions-neutral, extended, and flexed, their cervical spine musculoskeletal responses were measured. Data verified the occurrence of fatigue and revealed fatigue-induced neck deflection which increased cervical lordosis or kyphosis by 4-5° to 11°, depending on the neck position. This finding and its interpretations render a renewed understanding of muscle fatigue from a more unified motor control perspective as well as profound implications on neck pain and injury prevention.
Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
Mother-baby pairs recruited antenatally or at delivery, with babies eligible for inclusion if they are born at 34 weeks gestational age and above. Used as primary data for modelling.
A randomized, double-blinded, controlled, cross-over trial was conducted to verify the effects of chitosan oligosaccharide (GO2KA1). forty healthy male and female subjects aged 20-75 years with normal blood glucose, impaired fasting glucose and impaired glucose tolerance were recruited. The subjects visited the research site twice over with a seven-day interval after an overnight fast at least 12 hr. On the screening visit, the participants were the 2-hr oral glucose tolerance test (OGTT) was conducted. And they were separated normal blood glucose, impaired fasting glucose and impaired glucose tolerance. On the first visit, the participants were randomly assigned to consume a test or placebo product \[test product: chitosan oligosaccharide powder 500mg (GO2KA1); placebo product: white egg powder 500mg\] and ingested the assigned product. On the second visit, the participants consumed the other product that they did not eat on the first visit. On both visit day, the 2-hr oral sucrose tolerance test (OSTT) was conducted and started at 8:00 in the morning; venous blood samples were collected before (0 hr) and after ingestion (0.5, 1 and 2 hr) of the products.
1397593 Making tubes; shearing KABELUND METALLWERKE GUTEHOFFNUNGSHUTTE AG 4 Aug 1972 [16 Aug 1971] 23329/74 Divided out of 1397592 Headings B3A and B3W In the forming from metal strip of a tube from which edge portions of the strip project radially, the edge portions are trimmed by cutter discs 1, 2, the disc 1 being opposed by a guide disc 6, and the trimmed edge portions are welded or soldered. The spacing between discs 1 and 6 is variable by means of a screw 5 and between the cutters 1 and 2 by means of the eccentric mounting of the cutter 2. A guide 7, (of e.g. polyethylene, for the tube is slit to accommodate the upstanding edge portions. At least one of the cutter discs may be wetted by an impregnation agent to prevent cold welding of the strip to the disc(s). Downstream of the cutters there may be a pressure roller to hold the strip edge portions together to guide them to the welding means (not shown), A clamp for holding the slit in guide 7 to the required width is preferably associated with a cover plate serving as a heat shield. A waste-deflector roller may be mounted above and coaxially with the disc 1. is
The invention provides a peanut allergen polypeptide, a screening method and application thereof. Conformational epitopes of Ara h5 and Ara h 8 proteins were screened using phage display technology. Polyclonal IgE and IgG antibodies against the proteins of interest were prepared by immunizing BALB/c mice with Ara h5 and Ara h 8 proteins as antigens. ELISA and dot immunoblotting detection show that the titers of the polyclonal IgG and IgE of the anti-Ara h5 and Ara h 8 proteins are respectively 1: 64000. 1:320, and the antibody has specificity. The antibodies are used as targets, and conformational epitope sequences of Ara h5 protein are WETIYSR and FHWWYLK through phage display technology screening. Conformational epitopes of Ara h 8 protein were FPYMKFV, FPYMKFR, SMFARID and SFHWWLF.
FIELD: medicine, pharmacy. SUBSTANCE: method involves preparing mass for tabletting as a mixture of powder-like components: paracetamol, starch, caffeine and cacao. Mixture is wetted with citric acid and starch paste solutions which are mixed preliminary. To wetted mass acetylsalicylic acid ground to particle size 100-300 mcm is added and a mixture of acetylsalicylic acid with wetted mass is stirred for 5-8 min. Then wetted mass is subjected for moist granulation, dried, powdered with talc and calcium stearate, subjected for dry granulation and tabletted. For wetting 45-55% solution of citric acid and 6-10% solution of starch paste are used taken at volume ratio = (0.8-1.2): 7. Method provides an uniform distribution of acetylsalicylic acid in mass for tabletting, improves indices of strength and abradability of analgetic and antipyretic tablets proposed. EFFECT: improved method of preparing, improved quality and properties of tablets. 4 cl, 1 ex
For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. For examination of fundus, instill one or two drops of 0.5% solution 15 or 20 minutes prior to examination. Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will reverse spontaneously with time, typically in 4 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.
For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage is 2.2 mg/kg of body weight administered every 12 hours. Children weighing 45 kg or more should receive the adult dose. (See WARNINGS and PRECAUTIONS.)

For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.

The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage. 

When used in streptococcal infections, therapy should be continued for 10 days. 

Administration of adequate amounts of fluid along with the tablet form of drug in the tetracycline class is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.) 

If gastric irritation occurs, it is recommended that doxycycline be given with food or milk. The absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. 

Studies to date have indicated that administration of doxycycline at the usual recommended doses does not lead to excessive accumulation of doxycycline in patients with renal impairment.
The AGT arm includes a 2-step medication monotherapy and a combination treatment algorithm. The first step (level 1) includes two medication monotherapy options: escitalopram and mirtazapine. For those participants who don't remit with the initial intervention after up to 6 to 12-week treatment, the second step (level 2) with a variety of treatment options will be provided. In level 2 intervention, a switch strategy for those who don't remit with escitalopram will be switched to mirtazapine, or for those who don't remit with mirtazapine will be switched to escitalopram, combination strategy (i.e. escitalopram plus mirtazapine) and augmentation strategy (i.e. escitalopram or mirtazapine plus either rTMS or mECT). Participants who don't get remission in level 1 intervention will be encouraged to enter level 2 interventions based on intend-to-treatment principle. The TAU arm as control intervention is performed using the psychiatrist's individual discretion based on his/her expertise and knowledge.

Participants will be recruited consecutively in 8 psychiatric settings across China and randomized into any of the two initial interventions of AGT or TAU arm. Follow-up interviews will be performed monthly for all participants who finish any acute treatment of AGT or TAU. The follow-up period will last up to 6 months.
Selective lymph node dissection is an important idea to reduce the trauma of mediastinal lymph node dissection in early clinical patients. In a previous study, our team proposed a predictive model for mediastinal lymph node metastasis in patients with clinical T1N0 non-small cell lung cancer, and found that age, tumor size, central type, and pathologic subtype were closely related to mediastinal lymph node metastasis. In addition, our team found that adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma with predominantly adherent subtype (LPA) did not have mediastinal lymph node metastasis, and lymph node dissection was not necessary for such patients. In addition, by retrospectively studying nearly 3,000 cases of stage I-III NSCLC, we found that NSCLCs in the apical segments do not metastasize to the lower mediastinum, whereas in N1 lymph node-negative patients with negative pleural invasion, tumors in segments of the upper lobes do not metastasize to the lower mediastinal lymph nodes. On this basis, we conducted the first international prospective phase II clinical trial of a selective lymph node dissection strategy to validate the clinical feasibility of a selective lymph node dissection strategy. The main objective of this study was to develop a selective lymph node dissection strategy for cT1NOM0 invasive NSCLC with a diameter of ≤2 cm, i.e., no lower mediastinal lymph node dissection for tumors located in the upper lobe, and no upper mediastinal lymph node dissection for tumors located in the lower lobe. Further, we retrospectively analyzed 7067 NSCLC cases with systematic lymph node dissection from April 2008 to July 2022, in which the rate of mediastinal lymph node metastasis was 15.4% (1091/7067), and there was no lymph node metastasis in 209 cases of AIS/MIA/LPA, whereas in other subtypes of adenocarcinomas, the rate of mediastinal lymph node metastasis was 15.3% (106 /695). Among them, we retrospectively analyzed 360 cases of cT1N0M0 non-small cell lung cancer with 0.5 \< CTR \< 1.0 and found that among them, tumors located in the upper lobe had no lower mediastinal lymph node metastasis, and tumors located in the lower lobe had no metastasis in the upper mediastinal lymph nodes. For other non-small cell lung cancers with 0.5 \< CTR \< 1.0, if the VPI was negative, no lower mediastinal metastasis was also observed in tumors in the upper lobe and no upper mediastinal metastasis was observed in tumors in the lower lobe. In 212 cases of lung cancer not exceeding 1 cm in size, there were no lower mediastinal metastases in tumors in the upper lobe and no upper mediastinal metastases in tumors in the lower lobe.

The study investigated the efficacy and safety of a sex-selective lymph node strategy (no lower mediastinal lymph node clearance for upper lobe tumors and no upper mediastinal lymph node clearance for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.
The present invention relates to oral administration liquid for the elder, which aims at solving scarce potables problem for the elder. The oral administration liquid comprises the following raw materials in weight proportions: 7 to 26 proportions of birch yellow and 20 to 90 proportions of extracting solution of ganoderma lucidum. The raw materials also comprise 30 to 120 proportions of ginseng  and 10 to 30 proportions of propolis. The birch yellow is milled into birch bloom with a particle size of 250 meshes. The ginseng is the milled into ginseng powder with a particle size of 250 meshes. The oral administration liquid is produced in the following method: the birch yellow and ginseng are respectively milled into 250 meshes, which are then produced into the oral administration liquid together with the extracting solution of ganoderma lucidum, the propolis and other auxiliary materials in accordance with the conventional oral administration liquid preparation method. The oral administration liquid is produced with the common invigorant for the elder. The oral administration liquid has functions of strengthening by means of tonics, brain nourishment, diminishing inflammation, diuresis, tonifying the kidney, preventing various diseases and prolonging life.
ZYPITAMAG may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including pitavastatin.

Risk Factors for Myopathy   
Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use of certain drugs (including other lipid-lowering therapies), and higher ZYPITAMAG dosage [see Dosage and Administration (2.2), Drug Interactions (7), and Use in Specific Populations (8.5, 8.6)]. Dosages of pitavastatin greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. The maximum recommended dose of ZYPITAMAG is 4 mg once daily.

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis   
ZYPITAMAG is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil [see Contraindications (4) and Drug Interactions (7)]. There are pitavastatin dosage restrictions for patients taking erythromycin or rifampin [see Dosage and Administration (2.4)]. The following drugs when used concomitantly with ZYPITAMAG may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1 grams/day), fibrates, and colchicine [see Drug Interactions (7)].

Discontinue ZYPITAMAG if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if ZYPITAMAG is discontinued. Temporarily discontinue ZYPITAMAG in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the ZYPITAMAG dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
VIGIV is a solvent/detergent-treated, filtered sterile solution of purified gamma globulin (IgG) fraction of human plasma containing antibodies to vaccinia virus. It is stabilized with 10% maltose and 0.03% polysorbate 80 (pH is between 5.0 and 6.5) and contains no preservative. The product is a clear to opalescent liquid.

VIGIV is manufactured from plasma collected from healthy, screened donors with high titers of anti-vaccinia antibody (meeting minimum potency specifications) that is purified by an anion-exchange column chromatography method (3, 4). The plasma donors were boosted with vaccinia vaccine prior to donating plasma used in the production of the product. Each plasma donation used for the manufacture of VIGIV is tested for the presence of hepatitis B virus (HBV) surface antigen (HBsAg) and antibodies to human immunodeficiency viruses (HIV) 1/2 and hepatitis C virus (HCV) using FDA-licensed serological tests.

Plasma used in the manufacture of this product was tested by FDA licensed Nucleic Acid Testing (NAT) for HIV-1 and HCV and found to be negative. A NAT for HBV was also performed on all Source Plasma used and found to be negative; however, the significance of a negative result has not been established. The Source Plasma has also been tested by NAT for hepatitis A virus (HAV) and parvovirus B19 and the limit for B19 in the manufacturing pool is set not to exceed 104 IU of B19 DNA per mL.

The manufacturing process contains two steps implemented specifically for virus clearance. The solvent and detergent step (using tri-n-butyl phosphate and Triton X-100) is effective in the inactivation of enveloped viruses, such as HBV, HCV and HIV (5). Virus filtration, using a Planova 20N virus filter, is effective for the removal of viruses based on their size, including some non-enveloped viruses (6). In addition to the two specific steps, the anion-exchange chromatography step contributes to the removal of small non–lipid enveloped viruses.

The inactivation and reduction of known enveloped and non–enveloped model viruses were validated in laboratory studies as summarized in Table 2.

The product potency (as determined by a plaque reduction neutralization test) is expressed in arbitrary units (U) by comparison to the FDA reference standard. Each vial contains approximately 40 to 80 mg/mL total protein and ≥50,000 units of vaccinia antibody neutralizing activity. The product contains ≤40 mcg/mL of Immune globulin A (IgA).
Misexpression of the E3 ubiquitin ligase gene UBE3A is thought to contribute to a range of neurological disorders. In the context of Dup15q syndrome, additional genomic copies of UBE3A give rise to the autism, muscle hypotonia and spontaneous seizures characteristics of the disorder. In a Drosophila model of Dup 15q syndrome, it was recently shown that glial-driven expression of the UBE3A ortholog dube3a led to a "bang-sensitive" phenotype, where mechanical shock triggers convulsions, suggesting glial dube3a expression contributes to hyperexcitability in flies. Here we directly compare the consequences of glial- and neuronal-driven dube3a expression on motor coordination and seizure susceptibility in Drosophila. To quantify seizure-related behavioral events, we developed and trained a hidden Markov model that identified these events based on automated video tracking of fly locomotion. Both glial and neuronal driven dube3a expression led to clear motor phenotypes. However, only glial-driven dube3a expression displayed spontaneous seizure-associated immobilization events, that were clearly observed at high-temperature (38 °C). Using a tethered fly preparation amenable to electrophysiological monitoring of seizure activity, we found glial-driven dube3a flies display aberrant spontaneous spike discharges which are bilaterally synchronized. Neither neuronal-dube3a overexpressing flies, nor control flies displayed these firing patterns. We previously performed a drug screen for FDA approved compounds that can suppress bang-sensitivity in glial-driven dube3a expressing flies and identified certain 5-HT modulators as strong seizure suppressors. Here we found glial-driven dube3a flies fed the serotonin reuptake inhibitor vortioxetine and the 5-HT2A antagonist ketanserin displayed reduced immobilization and spike bursting, consistent with the previous study. Together these findings highlight the potential for glial pathophysiology to drive Dup15q syndrome-related seizure activity.
Type I diabetes is an autoimmune disease mediated by T-cell destruction of β cells in pancreatic islets. Currently, there is no known cure, and treatment consists of daily insulin injections. Genome-wide association studies and twin studies have indicated a strong genetic heritability for type I diabetes and implicated several genes. As most strongly associated variants are noncoding, there is still a lack of identification of functional and, therefore, likely causal variants. Given that many of these genetic variants reside in enhancer elements, we have tested 121 CD4+ T-cell enhancer variants associated with T1D. We found four to be functional through massively parallel reporter assays. Three of the enhancer variants weaken activity, while the fourth strengthens activity. We link these to their cognate genes using 3D genome architecture or eQTL data and validate them using CRISPR editing. Validated target genes include CLEC16A and SOCS1. While these genes have been previously implicated in type 1 diabetes and other autoimmune diseases, we show that enhancers controlling their expression harbor functional variants. These variants, therefore, may act as causal type 1 diabetic variants.
Severe and fatal hepatotoxicity, including hepatitis and hepatic failure, has occurred with the use of clofarabine injection. In clinical studies, Grade 3 to 4 liver enzyme elevations were observed in pediatric patients during treatment with clofarabine at the following rates: elevated aspartate aminotransferase (AST) occurred in 36% of patients; elevated alanine aminotransferase (ALT) occurred in 44% of patients. AST and ALT elevations typically occurred within 10 days of clofarabine administration and returned to Grade 2 or less within 15 days. Grade 3 or 4 elevated bilirubin occurred in 13% of patients, with 2 events reported as Grade 4 hyperbilirubinemia (2%), one of which resulted in treatment discontinuation and one patient had multiorgan failure and died. Eight patients (7%) had Grade 3 or 4 elevations in serum bilirubin at the last time point measured; these patients died due to sepsis and/or multiorgan failure. Monitor hepatic function, and for signs and symptoms of hepatitis and hepatic failure. Discontinue clofarabine injection immediately for Grade 3 or greater liver enzyme and/or bilirubin elevations [see Dosage and Administration (2.4)].